December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Verastem, Inc. - Common Stock (NQ:VSTM)

7.740 -0.060 (-0.77%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 25, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,061,074
Open 7.860
Bid (Size) 7.740 (300)
Ask (Size) 7.770 (1,200)
Prev. Close 7.800
Today's Range 7.670 - 7.890
52wk Range 3.430 - 10.82
Shares Outstanding 77,740,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Verastem Oncology Announces Late-Breaking Oral Presentation of RAMP 201 Low-Grade Serous Ovarian Cancer Molecular Profiling and Tumor Biomarker Analysis at IGCS 2026 Annual Global Meeting
From Verastem Oncology
Via Business Wire
News headline image
Verastem Highlights Ovarian Cancer Launch, KRAS G12D Program at H.C. Wainwright ↗
Verastem (NASDAQ:VSTM) executives outlined the company’s commercial and clinical priorities at an H.C. Wainwright event, highlighting the launch of its AVMAPKI FAKZYNJA CO-PACK for KRAS-mutated... 
Via MarketBeat

Performance

YTD
+7.1%
+7.1%
1 Month
+4.7%
+4.7%
3 Month
+104.8%
+104.8%
6 Month
+53.6%
+53.6%
1 Year
-10.1%
-10.1%

More News

Read More
News headline image
Verastem Oncology to Unveil New Clinical Data Highlighting the Best-in-Class Potential of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, Across Pancreatic, Lung, and Colorectal Cancers
From Verastem Oncology
Via Business Wire
Verastem Inc (NASDAQ:VSTM) Mixed Q1 Results Disappoint on Revenue Miss ↗
Via Chartmill
News headline image
Verastem Oncology to Participate in Upcoming September Investor Conferences
From Verastem Oncology
Via Business Wire
News headline image
Verastem (VSTM) Q2 2026 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Verastem Q2 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
News headline image
Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Doses First Patient in TARGET-D 203 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Colorectal Cancer
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology to Report Second Quarter 2026 Financial Results on August 6, 2026
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Doses First Patient in TARGET-D 202 Phase 2 Registration-Directed Trial of VS-7375 for KRAS G12D-Mutated Advanced Non-Small Cell Lung Cancer
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Verastem Oncology
Via Business Wire
News headline image
VS-7375 Demonstrates Clinical Activity with a Favorable Safety and Tolerability Profile in TARGET-D 101 Phase 1/2 Clinical Trial in Patients with Advanced KRAS G12D-Mutated Solid Tumors
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in First-Line Metastatic Pancreatic Cancer
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Doses First Patient in TARGET-D 201 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Pancreatic Cancer
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology to Host Investor Conference Call and Report Updated Data and Progress Across VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor TARGET-D Clinical Program
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Announces U.S. FDA Fast Track Designation for VS-7375, an Oral and Potential Best-in-Class Investigational KRAS G12D (ON/OFF) Inhibitor for the Treatment of KRAS G12D-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology to Present at Jefferies Healthcare Conference
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Appoints Michael P. Bailey to its Board of Directors
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology to Present at Upcoming Investor Conferences
From Verastem Oncology
Via Business Wire
News headline image
Verastem Q1 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
News headline image
Verastem (VSTM) Q1 2026 Earnings Transcript ↗
Via The Motley Fool
News headline image
On World Ovarian Cancer Day, LGSOC Resource Guide Launches to Support People Living with Low-Grade Serous Ovarian Cancer
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Launches HCP and Patient Reimagine Campaign to Increase Awareness of AVMAPKI® FAKZYNJA® CO-PACK for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer
From Verastem Oncology
Via Business Wire

Frequently Asked Questions

Is Verastem, Inc. - Common Stock publicly traded?
Yes, Verastem, Inc. - Common Stock is publicly traded.
What exchange does Verastem, Inc. - Common Stock trade on?
Verastem, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Verastem, Inc. - Common Stock?
The ticker symbol for Verastem, Inc. - Common Stock is VSTM on the Nasdaq Stock Market
What is the current price of Verastem, Inc. - Common Stock?
The current price of Verastem, Inc. - Common Stock is 7.740
When was Verastem, Inc. - Common Stock last traded?
The last trade of Verastem, Inc. - Common Stock was at 09/25/26 04:00 PM ET
What is the market capitalization of Verastem, Inc. - Common Stock?
The market capitalization of Verastem, Inc. - Common Stock is 601.71M
How many shares of Verastem, Inc. - Common Stock are outstanding?
Verastem, Inc. - Common Stock has 602M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.